Additionally, glucocorticoids displayed potent and selective activity against AML cells bearing t(8;21) translocation resulting in RUNX1-ETO fusion formation, and strong synergy when combined with chemotherapeutics [43]. The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.